{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:22:45Z","timestamp":1791400965543,"version":"4.3.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T00:00:00Z","timestamp":1355702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T00:00:00Z","timestamp":1355702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1038\/cmi.2012.39","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T13:15:15Z","timestamp":1355750115000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":168,"title":["What lessons can be learned from \u03b3\u03b4 T cell-based cancer immunotherapy trials?"],"prefix":"10.1038","volume":"10","author":[{"given":"Jean-Jacques","family":"Fourni\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Sicard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Poupot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bezombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Romagn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,17]]},"reference":[{"key":"BFcmi201239_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2174\/156652410793384150","volume":"10","author":"S Meraviglia","year":"2010","unstructured":"Meraviglia S, Caccamo N, Guggino G, Tolomeo M, Siragusa S, Stassi G et al. Optimizing tumor-reactive \u03b3\u03b4 T cells for antibody-based cancer immunotherapy. Curr Mol Med 2010; 10: 719\u2013726.","journal-title":"Curr Mol Med"},{"key":"BFcmi201239_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3410\/M2-45","volume":"2","author":"D Kabelitz","year":"2010","unstructured":"Kabelitz D . Human \u03b3\u03b4 T lymphocytes for immunotherapeutic strategies against cancer. F1000 Med Rep 2010; 2: 45.","journal-title":"F1000 Med Rep"},{"key":"BFcmi201239_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(11)70252-2","volume":"12","author":"V Kunzmann","year":"2011","unstructured":"Kunzmann V, Wilhelm M . Adjuvant zoledronic acid for breast cancer: mechanism of action? Lancet Oncol 2011; 12: 991\u2013992.","journal-title":"Lancet Oncol"},{"key":"BFcmi201239_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.it.2012.01.006","volume":"33","author":"D Hannani","year":"2012","unstructured":"Hannani D, Ma Y, Yamazaki T, Dechanet-Merville J, Kroemer G, Zitvogel L . Harnessing \u03b3\u03b4 T cells in anticancer immunotherapy. Trends Immunol 2012; 33: 199\u2013206.","journal-title":"Trends Immunol"},{"key":"BFcmi201239_CR5","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1073\/pnas.96.12.6879","volume":"96","author":"V Groh","year":"1999","unstructured":"Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T . Broad tumor-associated expression and recognition by tumor-derived \u03b3\u03b4 T cells of MICA and MICB. Proc Natl Acad Sci U S A 1999; 96: 6879\u20136884.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFcmi201239_CR6","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.4049\/jimmunol.175.8.5481","volume":"175","author":"M Corvaisier","year":"2005","unstructured":"Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E et al. V\u03b39V\u03b42T cell response to colon carcinoma cells. J Immunol 2005; 175: 5481\u20135488.","journal-title":"J Immunol"},{"key":"BFcmi201239_CR7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1586\/14737140.5.6.973","volume":"5","author":"E Viey","year":"2005","unstructured":"Viey E, Laplace C, Escudier B . Peripheral \u03b3\u03b4 T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2005; 5: 973\u2013986.","journal-title":"Expert Rev Anticancer Ther"},{"key":"BFcmi201239_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/314568","volume":"179","author":"J Dechanet","year":"1999","unstructured":"Dechanet J, Merville P, Berge F, Bone-Mane G, Taupin JL, Michel P et al. Major expansion of \u03b3\u03b4 T lymphocytes following cytomegalovirus infection in kidney allograft recipients. J Infect Dis 1999; 179: 1\u20138.","journal-title":"J Infect Dis"},{"key":"BFcmi201239_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/CJI.0b013e3181609988","volume":"31","author":"E Viey","year":"2008","unstructured":"Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, Caignard A . Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded V\u03b39V\u03b42 T cells from renal cell carcinoma patients. J Immunother 2008; 31: 313\u2013323.","journal-title":"J Immunother"},{"key":"BFcmi201239_CR10","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.4049\/jimmunol.180.5.3578","volume":"180","author":"BA Inman","year":"2008","unstructured":"Inman BA, Frigola X, Harris KJ, Kuntz SM, Lohse CM, Leibovich BC et al. Questionable relevance of \u03b3\u03b4 T lymphocytes in renal cell carcinoma. J Immunol 2008; 180: 3578\u20133584.","journal-title":"J Immunol"},{"key":"BFcmi201239_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ijc.10326","volume":"99","author":"BJ Zheng","year":"2002","unstructured":"Zheng BJ, Ng SP, Chua DT, Sham JS, Kwong DL, Lam CK et al. Peripheral \u03b3\u03b4 T-cell deficit in nasopharyngeal carcinoma. Int J Cancer 2002; 99: 213\u2013217.","journal-title":"Int J Cancer"},{"key":"BFcmi201239_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/ijc.1198","volume":"92","author":"BJ Zheng","year":"2001","unstructured":"Zheng BJ, Chan KW, Im S, Chua D, Sham JS, Tin PC et al. Anti-tumor effects of human peripheral \u03b3\u03b4 T cells in a mouse tumor model. Int J Cancer 2001; 92: 421\u2013425.","journal-title":"Int J Cancer"},{"key":"BFcmi201239_CR13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.4049\/jimmunol.1100681","volume":"187","author":"AH Capietto","year":"2011","unstructured":"Capietto AH, Martinet L, Fournie JJ . Stimulated \u03b3\u03b4 T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer. J Immunol 2011; 187: 1031\u20131038.","journal-title":"J Immunol"},{"key":"BFcmi201239_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00262-008-0571-9","volume":"58","author":"T Yuasa","year":"2009","unstructured":"Yuasa T, Sato K, Ashihara E, Takeuchi M, Maita S, Tsuchiya N et al. Intravesical administration of \u03b3\u03b4 T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 2009; 58: 493\u2013502.","journal-title":"Cancer Immunol Immunother"},{"key":"BFcmi201239_CR15","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1182\/blood-2008-08-172296","volume":"113","author":"J Gertner-Dardenne","year":"2009","unstructured":"Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 2009; 113: 4875\u20134884.","journal-title":"Blood"},{"key":"BFcmi201239_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/bjc.2011.293","volume":"105","author":"AJ Nicol","year":"2011","unstructured":"Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K et al. Clinical evaluation of autologous \u03b3\u03b4 T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 2011; 105: 778\u2013786.","journal-title":"Br J Cancer"},{"key":"BFcmi201239_CR17","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1136\/bjo.83.9.1069","volume":"83","author":"AA Bialasiewicz","year":"1999","unstructured":"Bialasiewicz AA, Ma JX, Richard G . \u03b1\/\u03b2\u2212 and \u03b3\/\u03b4 TCR+ lymphocyte infiltration in necrotising choroidal melanomas. Br J Ophthalmol 1999; 83: 1069\u20131073.","journal-title":"Br J Ophthalmol"},{"key":"BFcmi201239_CR18","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1158\/0008-5472.CAN-08-3037","volume":"69","author":"C Devaud","year":"2009","unstructured":"Devaud C, Bilhere E, Loizon S, Pitard V, Behr C, Moreau J et al. Antitumor activity of \u03b3\u03b4 T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model. Cancer Res 2009; 69: 3971\u20133978.","journal-title":"Cancer Res"},{"key":"BFcmi201239_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.immuni.2007.05.020","volume":"27","author":"G Peng","year":"2007","unstructured":"Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF . Tumor-infiltrating \u03b3\u03b4 T cells suppress T and dendritic cell function via mechanisms controlled by a unique Toll-like receptor signaling pathway. Immunity 2007; 27: 334\u2013348.","journal-title":"Immunity"},{"key":"BFcmi201239_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0008-8749(03)00066-2","volume":"221","author":"Y Ke","year":"2003","unstructured":"Ke Y, Kapp LM, Kapp JA . Inhibition of tumor rejection by \u03b3\u03b4 T cells and IL-10. Cell Immunol 2003; 221: 107\u2013114.","journal-title":"Cell Immunol"},{"key":"BFcmi201239_CR21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/BF03401961","volume":"7","author":"H Sicard","year":"2001","unstructured":"Sicard H, Al Saati T, Delsol G, Fournie JJ . Synthetic phosphoantigens enhance human V\u03b39V\u03b42 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol Med 2001; 7: 711\u2013722.","journal-title":"Mol Med"},{"key":"BFcmi201239_CR22","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.4049\/jimmunol.1103710","volume":"188","author":"J Gertner-Dardenne","year":"2012","unstructured":"Gertner-Dardenne J, Castellano R, Mamessier E, Garbit S, Kochbati E, Etienne A et al. Human V\u03b39V\u03b42 T cells specifically recognize and kill acute myeloid leukemic blasts. J Immunol 2012; 188: 4701\u20134708.","journal-title":"J Immunol"},{"key":"BFcmi201239_CR23","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.4049\/jimmunol.0903454","volume":"184","author":"M D'Asaro","year":"2010","unstructured":"D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M et al. V\u03b39V\u03b42 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 2010; 184: 3260\u20133268.","journal-title":"J Immunol"},{"key":"BFcmi201239_CR24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384","volume":"96","author":"V Kunzmann","year":"2000","unstructured":"Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M . Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 384\u2013392.","journal-title":"Blood"},{"key":"BFcmi201239_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1365-2141.2007.06754.x","volume":"139","author":"M Burjanadze","year":"2007","unstructured":"Burjanadze M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C et al. In vitro expansion of \u03b3\u03b4 T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 2007; 139: 206\u2013216.","journal-title":"Br J Haematol"},{"key":"BFcmi201239_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1215\/15228517-2008-111","volume":"11","author":"NL Bryant","year":"2009","unstructured":"Bryant NL, Suarez-Cuervo C, Gillespie GY, Markert JM, Nabors LB, Meleth S et al. Characterization and immunotherapeutic potential of \u03b3\u03b4 T-cells in patients with glioblastoma. Neuro Oncol 2009; 11: 357\u2013367.","journal-title":"Neuro Oncol"},{"key":"BFcmi201239_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12026-009-8114-9","volume":"45","author":"LS Lamb Jr","year":"2009","unstructured":"Lamb LS Jr . \u03b3\u03b4 T cells as immune effectors against high-grade gliomas. Immunol Res 2009; 45: 85\u201395.","journal-title":"Immunol Res"},{"key":"BFcmi201239_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ijc.20445","volume":"112","author":"D Kabelitz","year":"2004","unstructured":"Kabelitz D, Wesch D, Pitters E, Zoller M . Potential of human \u03b3\u03b4 T lymphocytes for immunotherapy of cancer. Int J Cancer 2004; 112: 727\u2013732.","journal-title":"Int J Cancer"},{"key":"BFcmi201239_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2781","volume":"10","author":"M Bonneville","year":"2010","unstructured":"Bonneville M, O'Brien RL, Born WK . \u03b3\u03b4 T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010; 10: 467\u2013478.","journal-title":"Nat Rev Immunol"},{"key":"BFcmi201239_CR30","first-page":"17","volume":"3","author":"C Belmant","year":"2006","unstructured":"Belmant C, Decise D, Fournie JJ . Phosphoantigens and aminobisphosphonates: New leads targeting \u03b3\u03b4 T lymphocytes for cancer immunotherapy. Drug Discov Today 2006; 3: 17\u201323.","journal-title":"Drug Discov Today"},{"key":"BFcmi201239_CR31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1359\/JBMR.0301230","volume":"19","author":"K Thompson","year":"2004","unstructured":"Thompson K, Rogers MJ . Statins prevent bisphosphonate-induced \u03b3,\u03b4-T-cell proliferation and activation in vitro. J Bone Miner Res 2004; 19: 278\u2013288.","journal-title":"J Bone Miner Res"},{"key":"BFcmi201239_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","volume":"102","author":"M Wilhelm","year":"2003","unstructured":"Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T et al. \u03b3\u03b4 T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102: 200\u2013206.","journal-title":"Blood"},{"key":"BFcmi201239_CR33","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","volume":"102","author":"F Dieli","year":"2003","unstructured":"Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F et al. Induction of \u03b3\u03b4 T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003; 102: 2310\u20132311.","journal-title":"Blood"},{"key":"BFcmi201239_CR34","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","volume":"60","author":"JM Lang","year":"2011","unstructured":"Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G et al. Pilot trial of interleukin-2 and zoledronic acid to augment \u03b3\u03b4 T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother 2011; 60: 1447\u20131460.","journal-title":"Cancer Immunol Immunother"},{"key":"BFcmi201239_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3727\/096504010X12671222663638","volume":"18","author":"M Naoe","year":"2010","unstructured":"Naoe M, Ogawa Y, Takeshita K, Morita J, Shichijo T, Fuji K et al. Zoledronate stimulates \u03b3\u03b4 T cells in prostate cancer patients. Oncol Res 2010; 18: 493\u2013501.","journal-title":"Oncol Res"},{"key":"BFcmi201239_CR36","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","volume":"67","author":"F Dieli","year":"2007","unstructured":"Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G et al. Targeting human \u03b3\u03b4 T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67: 7450\u20137457.","journal-title":"Cancer Res"},{"key":"BFcmi201239_CR37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","volume":"161","author":"S Meraviglia","year":"2010","unstructured":"Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G et al. In vivo manipulation of V\u03b39V\u03b42 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010; 161: 290\u2013297.","journal-title":"Clin Exp Immunol"},{"key":"BFcmi201239_CR38","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00262-010-0879-0","volume":"59","author":"J Bennouna","year":"2010","unstructured":"Bennouna J, Levy V, Sicard H, Senellart H, Audrain M, Hiret S et al. Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a V\u03b39V\u03b42 T lymphocyte agonist in patients with solid tumors. Cancer Immunol Immunother 2010; 59: 1521\u20131530.","journal-title":"Cancer Immunol Immunother"},{"key":"BFcmi201239_CR39","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00262-008-0491-8","volume":"57","author":"J Bennouna","year":"2008","unstructured":"Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C et al. Phase-I study of Innacell \u03b3\u03b4, an autologous cell-therapy product highly enriched in \u03b39\u03b42 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008; 57: 1599\u20131609.","journal-title":"Cancer Immunol Immunother"},{"key":"BFcmi201239_CR40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00262-006-0199-6","volume":"56","author":"H Kobayashi","year":"2007","unstructured":"Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T et al. Safety profile and anti-tumor effects of adoptive immunotherapy using \u03b3-\u03b4 T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007; 56: 469\u2013476.","journal-title":"Cancer Immunol Immunother"},{"key":"BFcmi201239_CR41","first-page":"1027","volume":"31","author":"H Kobayashi","year":"2011","unstructured":"Kobayashi H, Tanaka Y, Nakazawa H, Yagi J, Minato N, Tanabe K . A new indicator of favorable prognosis in locally advanced renal cell carcinomas: \u03b3\u03b4 T-cells in peripheral blood. Anticancer Res 2011; 31: 1027\u20131031.","journal-title":"Anticancer Res"},{"key":"BFcmi201239_CR42","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1080\/14653240802419328","volume":"10","author":"M Kondo","year":"2008","unstructured":"Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S et al. Zoledronate facilitates large-scale ex vivo expansion of functional \u03b3\u03b4 T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008; 10: 842\u2013856.","journal-title":"Cytotherapy"},{"key":"BFcmi201239_CR43","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","volume":"37","author":"Y Abe","year":"2009","unstructured":"Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T et al. Clinical and immunological evaluation of zoledronate-activated V\u03b39\u03b3\u03b4 T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009; 37: 956\u2013968.","journal-title":"Exp Hematol"},{"key":"BFcmi201239_CR44","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/14653249.2010.515581","volume":"13","author":"A Noguchi","year":"2011","unstructured":"Noguchi A, Kaneko T, Kamigaki T, Fujimoto K, Ozawa M, Saito M et al. Zoledronate-activated V\u03b39\u03b3\u03b4 T cell-based immunotherapy is feasible and restores the impairment of \u03b3\u03b4 T cells in patients with solid tumors. Cytotherapy 2011; 13: 92\u201397.","journal-title":"Cytotherapy"},{"key":"BFcmi201239_CR45","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.ejcts.2009.11.051","volume":"37","author":"J Nakajima","year":"2010","unstructured":"Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous \u03b3\u03b4 T cells. Eur J Cardiothorac Surg 2010; 37: 1191\u20131197.","journal-title":"Eur J Cardiothorac Surg"},{"key":"BFcmi201239_CR46","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.4049\/jimmunol.175.8.5471","volume":"175","author":"H Sicard","year":"2005","unstructured":"Sicard H, Ingoure S, Luciani B, Serraz C, Fournie JJ, Bonneville M et al. In vivo immunomanipulation of V\u03b39V\u03b42 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol 2005; 175: 5471\u20135480.","journal-title":"J Immunol"},{"key":"BFcmi201239_CR47","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2567.2008.02894.x","volume":"126","author":"V Kunzmann","year":"2009","unstructured":"Kunzmann V, Kimmel B, Herrmann T, Einsele H, Wilhelm M . Inhibition of phosphoantigen-mediated \u03b3\u03b4 T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells. Immunology 2009; 126: 256\u2013267.","journal-title":"Immunology"},{"key":"BFcmi201239_CR48","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.4049\/jimmunol.0901334","volume":"183","author":"R Casetti","year":"2009","unstructured":"Casetti R, Agrati C, Wallace M, Sacchi A, Martini F, Martino A et al. Cutting edge: TGF-beta1 and IL-15 induce FOXP3+ \u03b3\u03b4 regulatory T cells in the presence of antigen stimulation. J Immunol 2009; 183: 3574\u20133577.","journal-title":"J Immunol"},{"key":"BFcmi201239_CR49","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2008-06-162792","volume":"113","author":"G Gong","year":"2009","unstructured":"Gong G, Shao L, Wang Y, Chen CY, Huang D, Yao S et al. Phosphoantigen-activated V\u03b32V\u03b42 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection. Blood 2009; 113: 837\u2013845.","journal-title":"Blood"},{"key":"BFcmi201239_CR50","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.4049\/jimmunol.1000681","volume":"184","author":"AH Capietto","year":"2010","unstructured":"Capietto AH, Martinet L, Cendron D, Fruchon S, Pont F, Fournie JJ . Phosphoantigens overcome human TCRV\u03b39+ \u03b3\u03b4 Cell immunosuppression by TGF-\u03b2: relevance for cancer immunotherapy. J Immunol 2010; 184: 6680\u20136687.","journal-title":"J Immunol"},{"key":"BFcmi201239_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jim.2009.05.006","volume":"347","author":"S Salot","year":"2009","unstructured":"Salot S, Bercegeay S, Dreno B, Saiagh S, Scaglione V, Bonnafous C et al. Large scale expansion of V\u03b39V\u03b42 T lymphocytes from human peripheral blood mononuclear cells after a positive selection using MACS \u2018TCR \u03b3\/\u03b4+ T cell isolation kit\u2019. J Immunol Methods 2009; 347: 12\u201318.","journal-title":"J Immunol Methods"},{"key":"BFcmi201239_CR52","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/eji.200636343","volume":"37","author":"D Cendron","year":"2007","unstructured":"Cendron D, Ingoure S, Martino A, Casetti R, Horand F, Romagne F et al. A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct \u03b3\u03b4 and alphabeta T cell responses in primates. Eur J Immunol 2007; 37: 549\u2013565.","journal-title":"Eur J Immunol"},{"key":"BFcmi201239_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/CJI.0b013e318245bb1e","volume":"35","author":"V Kunzmann","year":"2012","unstructured":"Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J et al. Tumor-promoting versus tumor-antagonizing roles of \u03b3\u03b4 T cells in cancer immunotherapy: results from a prospective phase I\/II trial. J Immunother 2012; 35: 205\u2013213.","journal-title":"J Immunother"},{"key":"BFcmi201239_CR54","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/eji.201141870","volume":"42","author":"F Pont","year":"2012","unstructured":"Pont F, Familiades J, Dejean S, Fruchon S, Cendron D, Poupot M et al. The gene expression profile of phosphoantigen-specific human \u03b3\u03b4 T lymphocytes is a blend of alphabeta T-cell and NK-cell signatures. Eur J Immunol 2012; 42: 228\u2013240.","journal-title":"Eur J Immunol"},{"key":"BFcmi201239_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2009.03.011","volume":"124","author":"L Martinet","year":"2009","unstructured":"Martinet L, Poupot R, Fournie JJ . Pitfalls on the roadmap to \u03b3\u03b4 T cell-based cancer immunotherapies. Immunol Lett 2009; 124: 1\u20138.","journal-title":"Immunol Lett"},{"key":"BFcmi201239_CR56","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1007\/s00018-011-0705-7","volume":"68","author":"AH Capietto","year":"2011","unstructured":"Capietto AH, Martinet L, Fournie JJ . How tumors might withstand \u03b3\u03b4 T-cell attack. Cell Mol Life Sci 2011; 68: 2433\u20132442.","journal-title":"Cell Mol Life Sci"},{"key":"BFcmi201239_CR57","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.bcp.2010.05.002","volume":"80","author":"L Martinet","year":"2010","unstructured":"Martinet L, Jean C, Dietrich G, Fournie JJ, Poupot R . PGE2 inhibits natural killer and \u03b3\u03b4 T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochem Pharmacol 2010; 80: 838\u2013845.","journal-title":"Biochem Pharmacol"},{"key":"BFcmi201239_CR58","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/eji.200838812","volume":"39","author":"L Martinet","year":"2009","unstructured":"Martinet L, Fleury-Cappellesso S, Gadelorge M, Dietrich G, Bourin P, Fournie JJ et al. A regulatory cross-talk between V\u03b39V\u03b42 T lymphocytes and mesenchymal stem cells. Eur J Immunol 2009; 39: 752\u2013762.","journal-title":"Eur J Immunol"},{"key":"BFcmi201239_CR59","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","volume":"20","author":"M Challa-Malladi","year":"2011","unstructured":"Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV et al. Combined genetic inactivation of \u03b22-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011; 20: 728\u2013740.","journal-title":"Cancer Cell"},{"key":"BFcmi201239_CR60","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.humpath.2011.10.014","volume":"43","author":"LB Jilaveanu","year":"2012","unstructured":"Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL . CD70 expression patterns in renal cell carcinoma. Hum Pathol 2012; 43: 1394\u20139.","journal-title":"Hum Pathol"},{"key":"BFcmi201239_CR61","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1593\/neo.06451","volume":"8","author":"J Diegmann","year":"2006","unstructured":"Diegmann J, Junker K, Loncarevic IF, Michel S, Schimmel B, von Eggeling F . Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia 2006; 8: 933\u2013938.","journal-title":"Neoplasia"},{"key":"BFcmi201239_CR62","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1158\/0008-5472.CAN-06-0250","volume":"66","author":"K Biswas","year":"2006","unstructured":"Biswas K, Richmond A, Rayman P, Biswas S, Thornton M, Sa G et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res 2006; 66: 6816\u20136825.","journal-title":"Cancer Res"},{"key":"BFcmi201239_CR63","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood.V99.3.754","volume":"99","author":"G Cartron","year":"2002","unstructured":"Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc\u03b3RIIIa gene. Blood 2002; 99: 754\u2013758.","journal-title":"Blood"},{"key":"BFcmi201239_CR64","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1158\/1078-0432.CCR-10-1292","volume":"17","author":"G Cartron","year":"2011","unstructured":"Cartron G, Trappe RU, Solal-Celigny P, Hallek M . Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 2011; 17: 19\u201330.","journal-title":"Clin Cancer Res"},{"key":"BFcmi201239_CR65","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","volume":"8","author":"L Zitvogel","year":"2011","unstructured":"Zitvogel L, Kepp O, Kroemer G . Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8: 151\u2013160.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Cellular & Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cmi201239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cmi201239","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cmi201239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T10:08:21Z","timestamp":1672740501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cmi201239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,17]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["BFcmi201239"],"URL":"https:\/\/doi.org\/10.1038\/cmi.2012.39","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,17]]},"assertion":[{"value":"23 May 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}